Biocept, Inc.(Biocept) is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC), and circulating tumor Deoxyribonucleic acid (DNA), (ctDNA), tests utilizing a standard blood sample. These tests (including its OncoCEE-BRTM breast cancer CTC test, which is already on the market) are designed to provide information to oncologists to enable them to select appropriate treatment. Cell Enrichment and Extraction (CEE) is an internally invented and developed, microfluidics-based CTC capture and analysis platform. Circulating tumor cells are cancer cells that have detached from the tumor matrix and invaded the patient�s blood or other bodily fluids. OncoCEE CTC tests for cancer types other than breast cancer, with a focus on population solid tumor types, or cancers for which there are approved therapies that rely on biomarker tests.